What is the recommended management for vertebral artery stenosis?

Management of Vertebral Artery Stenosis

Medical therapy with antiplatelet agents and aggressive atherosclerotic risk factor modification is the recommended first-line treatment for vertebral artery stenosis, regardless of symptom status. 1, 2

Initial Diagnostic Approach

When vertebral artery stenosis is suspected:

• Use CTA or MRA for initial imaging rather than ultrasound, as these modalities provide superior visualization of the vertebral arteries, particularly at the origin 1, 2
• Perform noninvasive imaging in patients with posterior circulation symptoms (vertigo, diplopia, ataxia, bilateral visual disturbances) 1
• Consider imaging in asymptomatic patients with bilateral carotid occlusions or unilateral carotid occlusion with incomplete circle of Willis 1, 2

Medical Management (Class I Recommendations)

Antiplatelet Therapy

All patients with vertebral artery stenosis should receive antiplatelet therapy 2:

• Aspirin 75-325 mg daily (most commonly 81-325 mg) as first-line therapy
• Alternative options if aspirin is contraindicated:
  • Clopidogrel 75 mg daily, OR
  • Aspirin plus extended-release dipyridamole (25/200 mg twice daily)
  • Ticlopidine 250 mg twice daily (if clopidogrel intolerant) 1

Risk Factor Modification

Apply the same aggressive standards used for carotid atherosclerosis 2:

• Statin therapy for lipid management
• Blood pressure control
• Diabetes management
• Smoking cessation
• Lifestyle modifications

Special Consideration: Acute Symptomatic Disease

For patients with acute ischemic stroke or TIA in vertebral artery territory with angiographic evidence of thrombus:

• Anticoagulation for at least 3 months is generally recommended 1
• This applies whether or not thrombolytic therapy was initially used
• The WASID trial demonstrated aspirin and warfarin have equal efficacy for secondary prevention 1

Endovascular Treatment Considerations

The evidence does NOT support routine endovascular intervention (angioplasty/stenting) for vertebral artery stenosis. This is a critical distinction from carotid disease management.

Key Evidence Limitations:

• A 2026 Cochrane review of 4 RCTs (429 patients) found no clear benefit of endovascular treatment plus medical therapy versus medical therapy alone for any outcome including stroke, death, or recurrent TIA 3
• Three of four trials were stopped early due to lack of efficacy
• Low-certainty evidence with wide confidence intervals compatible with modest benefit or modest harm 3

When Revascularization May Be Reasonable (Class IIa):

For subclavian steal syndrome specifically (not isolated vertebral stenosis):

• Extra-anatomic carotid-subclavian bypass for symptomatic patients without high surgical risk 2
• Percutaneous angioplasty and stenting for high-risk surgical patients 2

Catheter Angiography Role:

• Reserve for patients who remain symptomatic despite medical therapy AND are being considered for revascularization
• Use only when noninvasive imaging fails to adequately define stenosis location or severity 1, 2

Follow-Up Strategy

For symptomatic patients on medical therapy:

• Serial noninvasive imaging (CTA or MRA) is reasonable to assess disease progression 1, 2
• No specific interval mandated, but similar approach to carotid surveillance is reasonable

For patients who undergo revascularization:

• Serial imaging at intervals similar to carotid revascularization (typically 1 month, 6 months, then annually) 2

Critical Clinical Pitfalls

1. Do not assume vertebral artery stenosis requires stenting like carotid disease does - the evidence base is fundamentally different
2. Distinguish vertebrobasilar symptoms from other causes - cardiac arrhythmias, orthostatic hypotension, and vestibular disorders can mimic posterior circulation ischemia 1
3. Asymptomatic vertebral stenosis does NOT warrant revascularization - medical therapy only 2
4. Recent observational data showing good technical results with stenting 4 should not override the lack of clinical benefit demonstrated in randomized trials 3

Algorithm Summary

1. Confirm diagnosis with CTA or MRA
2. Initiate medical therapy (aspirin + risk factor modification) for ALL patients
3. If acute symptomatic with thrombus: add anticoagulation for 3 months
4. If recurrent symptoms despite optimal medical therapy: consider catheter angiography only if revascularization is genuinely being contemplated
5. Endovascular intervention: reserve only for subclavian steal syndrome or highly selected cases in research settings

The evidence strongly favors a medical-first approach, with endovascular therapy lacking proven clinical benefit despite acceptable technical success rates.